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Background: To validate oral exfoliative cytology in the analysis of the microRNA expression profile in Oral 
Lichenoid Disease (OLD).
Material and methods: The expression of 13 microRNAs identified and presented by our group in a previous study 
was analyzed in 26 cases, 16 diagnosed as OLD and 10 controls with no oral mucosal pathology. Cytological 
samples from the oral mucosa obtained using an Orcellex toothbrush were analyzed using RT-qPCR and TaqMan 
microRNA assays. 
Results: The aberrant expression was validated for 2 microRNAs (miR-146a-5p and miR-7-1-3p) of those previ-
ously recognized in the biopsy study.
Conclusions: This is the first time that oral exfoliative cytology is validated in a study of the alterations of the 
expression of microRNAs in OLD. The alteration of miR-146a and miR-7 compared to controls was validated. 
These microRNAs are associated with both inflammatory and carcinogenic phenomena that are involved in the 
etiopathogenesis of this potentially malignant oral disorder. 
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Introduction
Oral lichenoid disease (OLD) is a chronic inflammatory 
disorder with an immunological base that is present 
in nearly 2% of the population, mainly affecting adult 
women (1,2). This disease is considered a potentially 
malignant oral disorder with a variable percentage of 
malignant transformation (0.4-6.5%) (3). To date, data 
that can predict the risk of malignant transformation of 
this disease and that help establish effective preventive 
measures to avoid such transformation remain unreli-
able (2,4).
In recent years, the interest in the use of oral exfoliative 
cytology has grown significantly. This minimally inva-
sive method helps us to obtain epithelial cells for the 
diagnosis of oral precancerous processes and for their 
molecular analysis (5-7).
MicroRNAs are non-coding RNA molecules that act in 
post-transcriptional regulation of gene expression and 
are partially complementarily bonded to the 3 ŕegion of 
the messenger RNA causing transcriptional repression 
or direct degradation of the mRNA (8,9). It is consid-
ered that the nearly 2000 microRNAs described can 
regulate the expression of 60% of the human genes and 
that they can also regulate biological processes such as 
growth, differentiation and cellular death (9). Evidence 
shows that microRNAs play an important role in cancer, 
possibly acting as oncogenes or tumor suppressor genes 
(10). Studies also outline changes in the expression pro-
file of these microRNAs during the malignant transfor-
mation of premalignant lesions into oral cancer (11,12). 
These molecules are very stable and can be easily de-
tected in various media such as paraffin-embedded tis-
sue samples, biological fluids and cytological samples, 
widening their potential for analysis (13,14).
Until now, few studies (15-17) have analyzed the ex-
pression profile of microRNAs in OLD, yet none of 
them using oral cytological samples. Obtaining RNA 
with a non-surgical approach may be ideal in detecting 
this potentially malignant oral disorder and its potential 
of malignant transformation.
In 2016, our group analyzed the expression of 768 ma-
ture microRNAs in the highest number of OLD samples 
studied so far (17). Of the 20 deregulated microRNAs, 
the 13 with a higher degree of deregulation were further 
validated in an independent set of samples.
With this background, we designed a study with the aim 
of assessing the viability of exfoliative cytology sam-
ples for the analysis of microRNA expression profile in 
OLD and its use in its diagnosis and its prognosis.
Material and Methods
-Patients and samples
Oral cytology samples from 26 individuals were ob-
tained from Oral Medicine Unit of the Dental Clinical 
Service (University of the Basque Country/EHU) and 
the Maxillofacial Surgery Service (Hospital Universi-
tario Araba-Osakidetza). The OLD group comprised 
16 patients (mean age, 63.7 years; range 45–78 years; 
female-to-male ratio, 3:1) with clinical and histopath-
ological diagnosis of OLD, according to the criteria 
previously described (1). The study included a control 
group that comprised 10 healthy patients without oral 
mucosa disorders (mean age, 57.5 years; range, 51–71 
years; female-to-male ratio, 4:1). Demographic char-
acteristics are shown in Table 1. None of the patients 
were smokers, consumed alcohol or were in any drug 
treatment. A cytological brush (Orcellex Brush, Rov-
ers Medical Devices, The Netherlands) was vigorously 
swabbed over the lesions in OLD and over the buccal 
and lingual mucosa in control group. The brush head 
was introduced into a sterile tube with RNA lysis buffer 
(Zymo Research, USA) and stored at -20 ° C.
This study was carried out in accordance with the prin-
ciples of the Declaration of Helsinki on Ethical Prin-
ciples for Medical Research Involving Human Subjects 
and was approved by the Ethics Committee for Re-
search of the University of the Basque Country/ EHU 
(CEISH/271/2014). In this study the methodology fol-
lowed was similar as previously described by Setién-
Olarra et al. (17). 
RNA isolation and microRNA quantitative RT-PCR 
analysis
Total RNA including microRNA obtained by brush cy-
tology was extracted using the Quick - RNA Miniprep 
 Groups (n = 26)
 OLD (n = 16) Control (n = 10)
Gender % (n) Female 75% (12) 80% (8)
Male 25% (4) 20% (2)
Age (years) Mean (SD) 63.7 (8.4) 57.5 (6.5)
 (min-max) 45-78 51-71
Table 1: Demographic characteristics of the patients included in the study
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kit (Zymo Research, USA). The purity and concentra-
tion of RNA were determined by OD260/280/230 read-
ings using a NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific, Eugene, OR, USA). RNA 
integrity was determined by fluorometric quantitation 
using the Qubit 3 Fluorometer (Life Technologies, Fos-
ter City, CA, USA).
Previously identified microRNAs were evaluated in an 
independent validation set of 26 oral cytology samples 
(16 OLD and 10 control) by RT-qPCR using TaqMan 
microRNA assays (Applied Biosystems). As reported 
(17), miR-30b, miR-26a, and miR-26b were proposed 
as candidate normalizers for the validation step. Each 
microRNA was spotted in triplicate, and no-template 
RT controls were carried along in each experiment. Ct 
values of the target microRNAs were normalized in re-
lation to that of the three normalize microRNAs, and 
microRNA expression levels [relative quantity (RQ)] 
were calculated using the comparative Ct method: Ct-
Sample–CtMeannormalizers.
-Data analysis
Pairwise comparisons of quantitative data obtained by 
RT-qPCR experiments were made by the Mann–Whit-
ney U test. All tests were two-sided, and microRNAs 
showing two-fold difference changes [fold change (FC) 
>2] between OLD vs normal and adjusted P-value <0.05 
were considered statistically significant. A binary logis-
tic regression analysis was performed in those cases 
were there was statistical significance. The statistical 
analyses in the validation phase were performed using 
SPSS v18.
Results
-Validation of differently expressed microRNAs
Our previous study (17) using oral biopsy samples in 
patients diagnosed with OLD showed an altered ex-
pression profile in 13 microRNAs (microRNA-150-5p, 
microRNA-142-5p, microRNA-146a-5p, microR-
NA-223-5p, microRNA-7-1-3p, microR¬NA-339-3p, 
microRNA-342-3p, microRNA-146b-5p, microRNA-
140-3p, microRNA-1247-5p, microRNA-152-3p, mi-
croRNA-625-5p, microRNA-629-3p). These 13 altered 
microRNAs were analyzed in the present study. Table 2 
shows the comparative results of these 13 microRNAs.
We compared the results of the aberrant expression in 
cytological samples with those obtained in our previous 
study on biopsy samples (17), and we were able to vali-
date significant differences in 2 microRNAs and show-
ing a significant overexpression (p<0.05) in the OLD 
group compared to the control group (miR-7-1-3p, miR-
146a-5p) (Table 2). Specifically, OLD samples show a 
3.7 times greater expression of miR-146a-5p than con-
trol samples (p=0.035). On the other hand, overexpres-
sion of miR-7-1-3p was 2-times greater in OLD when 
compared to the control group (p=0.003).
 OLD (n=16) vs Control (n=10)














Table 2: Biological validation of the 13 microRNAs selected.
*The statistically significant values are represented in bold. FC: Fold 
change. OLD: Oral Lichen Disease. 
Table 3 shows the results of the binary logistic regres-
sion analysis for the differently expressed microRNAs. 
Overexpression of miR-7-1-3p increases the risk of suf-
fering OLD. 
Discussion
OLD is a potentially malignant oral disorder that has, in 
most cases, an unknown and/or uncertain etiology and 
a malignant potential that varies widely (3, 18). In 2009, 
Cervigne et al. (11) suggested that microRNAs could 
be used to predict malignant transformation of prema-
lignant oral lesions. Following this line, our group (17) 
analyzed the expression pattern of 768 microRNAs in a 
significant number of patients, validating the profile of 
13 microRNAs with a different expression profile in the 
disease. Considering these results, we consider using 
oral cytology to diagnose and monitor these alterations 
with as a less invasive method and consequently, we 
aim to validate the results in oral cytological samples of 
a group of patients diagnosed with OLD.
In this study, we could only validate the alteration in 
the expression of 2 microRNAs (miR-146a-5p and miR-
7-1-3p) when comparing the OLD group with the con-
trol group. We were unable to validate the remaining 
altered microRNAs from the previous study in this set 
of samples, which indicates the existence of differences 
in the analysis of biopsy and cytology samples from 
these lesions. We believe that this is mainly due to the 
difference in the composition of the tissue and cells in 
each type of sample. Exfoliative cytology of the oral 
mucosa includes mainly superficial cells of the scraped 
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 OR crude (CI 95%) P - value OR (CI 95%)* P - value
hsa-miR-146a-5p 1.141 (0.971-1.340) 0.108 1.133 (0.987-1.299) 0.075
hsa-miR-7-1-3p 9.302 (1.457-59.369) 0.018 9.831 (1.244-77.721) 0.03
Table 3: Binary logistic regression results for statistically significant microRNAs.
*adjusted by sex and age
epithelial cells from the mucosa (mature keratinocytes) 
(5,19); while biopsy samples comprise the totality of the 
mucosa, including all the layers of epithelial cells, as 
well as connective tissue cells from the lamina propria. 
This situation was raised also by He et al. (7) in a study 
on tongue cancer samples in which the qualitative and 
quantitative differences in microRNA expression be-
tween the biopsy samples and cytology samples were 
observed.
MicroRNA-146a was validated extensively in our study 
and is the only microRNA that has been described in 
oral cancer and potentially malignant oral disorders in 
both complete genome and candidate gene studies (17, 
20, 21). Its implication in inflammatory and immuno-
logical processes, as well as in various neoplasms in-
cluding oral cancer, has been demonstrated (21-25). 
Recently, Zhang et al. (25) demonstrated that the allelic 
variants of miR-146a rs2910164 in a Chinese population 
may be associated with a higher risk of presenting head 
and neck squamous cell carcinoma. Based on these 
findings, we consider that microRNA-146a may be an 
important element in oral carcinogenesis by mediating 
the regulation of the proinflammatory pathways with a 
carcinogenic potential (26). Therefore, the early detec-
tion using a simple and non-invasive technique such as 
oral exfoliative cytology may contribute with valuable 
information in patients diagnosed with OLD in which 
we should apply careful monitoring. 
Regarding microRNA-7, its deregulation has been rec-
ognized in different malignant neoplasms, among which 
the oral squamous cell carcinoma is included (27-29). In 
2010, Jiang et al. (28) observed that microRNA-7 could 
cause the subexpression of the receptor of the IGF1R 
growth factor in cells of tongue squamous cell carci-
noma and could mitigate phosphorylation or activation 
of the AKT kinase protein, a protein associated with 
inflammatory processes mediated by cytokines (30), 
causing a reduction in cell proliferation and an enhance-
ment of apoptosis (28). Furthermore, our results show 
that overexpression of microRNA-7 increases the risk 
of presenting OLD. All this indicates that microRNA-7 
may have an oncogenic regulating role and a role in reg-
ulating certain inflammatory processes, among which 
the chronic inflammatory process of OLD is included. 
These initially promising results show certain limita-
tions due to the retrospective aspect and the size of the 
sample. In future studies, we suggest that a bigger sam-
ple is used in order to obtain stronger statistical results. 
It is possible that this will provide us with more answers 
in other validated microRNAs, such as hsa-miR-150-
5p, el hsa-miR-342-3p or hsa-miR-140-3p that showed 
p-values close to the 0.05 threshold.
In conclusion, our study is the first to analyze the vi-
ability of the oral exfoliative cytology for the study of 
the alterations of the expression of microRNAs in OLD. 
The alteration of miR-146a and miR-7 compared to con-
trols was validated. The aberrant expression of these 
microRNAs may be used in the diagnosis of OLD and 
in the individual prognostic assessment. 
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